Novartis MS drug remibrutinib meets Phase III trial goals

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. ACN

Go back to Novartis MS drug remibrutinib meets Phase III trial goals
NOVARTIS AG (NYSE: NVS) Delayed: 137.70 -22.29 (13.93%)
Previous Close $159.99    52 Week High $89.15 
Open $139.94    52 Week Low $69.84 
Day High $140.46    P/E N/A 
Day Low $137.12    EPS $0.00 
Volume 10,262,393